Better Coronavirus Stock: AstraZeneca or Moderna?
Over the last few months, AstraZeneca (NYSE: AZN) and Moderna (NASDAQ: MRNA) have emerged as frontrunners in the race for a coronavirus vaccine. Both vaccine efforts are in the midst of the final phase of clinical trials, and both companies are forging international collaborations with competitors, nonprofit groups, and government entities. Early successes have given way to hard setbacks in the clinical development process, yet each contender has rallied to push forward.
Moderna is an unproven biotech without any products on the market, whereas AstraZeneca is a pharmaceutical behemoth with a long history of successful launches. This dynamic is precisely why producing an effective coronavirus vaccine may have dramatically different impacts on each company. Thus, to unpack which is the better coronavirus stock, it’ll be necessary to place each company’s vaccine effort in the context of its competitive position.
Image source: Getty Images.